Placebo News and Research RSS Feed - Placebo News and Research

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. [More]
Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). [More]
CCC study provides hope that SapC-DOPS could be used for metastatic brain cancer treatment

CCC study provides hope that SapC-DOPS could be used for metastatic brain cancer treatment

Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases. [More]
Longer looks: the economics of infertility; placebos as treatment raises ethical dilemmas

Longer looks: the economics of infertility; placebos as treatment raises ethical dilemmas

About a decade ago, Medicaid programs were struggling to keep up with skyrocketing prescription drug costs. Between 1997 and 2002, drug spending in the program for low-income Americans grew by about 20 percent annually. ... Medicaid directors began looking for ways to tamp down on those costs. One of the most popular policies was something called "prior authorization" for a new wave of more expensive, anti-psychotic drugs ,... These policies, in a sense, worked: they helped rein in how much Medicaid spent filling prescriptions. But in another sense, they may not have worked at all: a growing body of research has begun questioning whether restricting drug spending may have just shifted costs elsewhere -; particularly, into the prison system (Sarah Kliff, 7/22). [More]
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). [More]
New treatment fights respiratory syncytial virus in children

New treatment fights respiratory syncytial virus in children

Researchers at Le Bonheur Children's Hospital and the University of Tennessee Health Science Center announced results of a clinical trial of a new drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV). [More]
Paracetamol fails to beat placebo at relieving back pain

Paracetamol fails to beat placebo at relieving back pain

Paracetamol is no more effective than placebo at relieving acute lower back pain, according to new clinical trial results. [More]
Zydelig gets FDA approval for treatment of patients with three types of blood cancers

Zydelig gets FDA approval for treatment of patients with three types of blood cancers

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. [More]
Long-acting inhaled combination therapy best for COPD

Long-acting inhaled combination therapy best for COPD

The combination of a long-acting β22-agonist and an inhaled corticosteroid may be the best choice for some patients with chronic obstructive pulmonary disease who need more than short-acting bronchodilators, suggest the results of a Cochrane Collaboration network meta-analysis. [More]
Parkinson's patients that respond favorably to sham surgery express distinct neurological profile

Parkinson's patients that respond favorably to sham surgery express distinct neurological profile

Parkinson's disease is the second most common neurological disorder, affecting almost 10 million people worldwide. [More]
Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. [More]
Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
Common genetic variation in gene may modify cardiovascular benefit of aspirin

Common genetic variation in gene may modify cardiovascular benefit of aspirin

Aspirin is the gold standard for antiplatelet therapy and a daily low-dose aspirin is widely prescribed for the prevention of cardiovascular disease. [More]
Scientists identify genes that may help predict steroid responsiveness in people with EoE

Scientists identify genes that may help predict steroid responsiveness in people with EoE

Results from a clinical trial show that high doses of the corticosteroid fluticasone propionate safely and effectively induce remission in many people with eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus characterized by high levels of white blood cells called eosinophils. [More]
Brain network measures placebo effects in Parkinson's disease patients

Brain network measures placebo effects in Parkinson's disease patients

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. [More]
Consumption of probiotics during 30 days helps diminish accumulation of fat in liver

Consumption of probiotics during 30 days helps diminish accumulation of fat in liver

Spanish scientists have demonstrated through an experiment on obese rats that the consumption of probiotics during thirty days helps diminish the accumulation of fat in the liver. [More]
Phase II study reveals potential biomarker for HIV vaccine

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine. [More]
Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

The U.S. affiliate of Ipsen today announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline Autogel / Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) achieved statistically significant prolongation of progression free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [More]
Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain. [More]
Phase III research shows that new drug improves symptoms related to plaque psoriasis

Phase III research shows that new drug improves symptoms related to plaque psoriasis

Randomized, phase III research from the University of Alabama at Birmingham shows that a new drug improves symptoms related to moderate to severe plaque psoriasis, a chronic skin disease of scaling and inflammation. [More]